Global Automated Injector Market Report 2021-2026: Increasing prevalence of targeted therapies, rising rate of anaphylaxis, and increasing number of regulatory approvals

Dublin, November 29, 2021– (work wire)–The Auto-injectors: Global Markets 2021-2026 Report added to an offer.

The global auto-injectors market should grow from $41.5 billion in 2021 to $85.2 billion by 2026, at a compound annual growth rate (CAGR) of 15.5% for the period from 2021 to 2026.

  • The North American auto syringe market should grow from $15.1 billion in 2021 to $28.4 billion by 2026, at a compound annual growth rate of 13.4% for the period from 2021 to 2026.

  • The Asia Pacific auto syringe market should grow from $10.2 billion in 2021 to $22.6 billion by 2026, at a compound annual growth rate of 17.2% for the period from 2021 to 2026.

The increasing prevalence of targeted therapies, the increasing incidence of anaphylaxis, and the increasing number of regulatory approvals are some of the factors responsible for the growth of this market.

Auto-injectors are pen-like devices used to deliver a steady dose of medication to a patient and are intended for self-administration. Self-injections are gradually becoming the gold standard in the treatment of indications such as anaphylaxis, multiple sclerosis, and rheumatoid arthritis. Most auto-injectors are spring-loaded, and the self-injection procedure is relatively simple.

These tools can help avoid needlestick injuries and reduce needle phobia in patients. Autoinjector manufacturers focus on user-centered approaches to improve ease of use and overcome anxiety associated with self-administration of intramuscular injections.

Auto-injectors are expected to present significant opportunities for investors due to the high demand for development of biopharmaceuticals. Since the procedure does not require a hospital or clinic visit, it reduces reliance on healthcare professionals. Increased adoption of auto-injectors with benefits such as increased safety, accuracy and minimal discomfort is expected to lead to market revenue growth over the forecast period.

The report also includes market forecasts to 2026 and ratings of the major market players. The report segments the Automated Injectors market based on product type, administration and treatment route, end user, and geography or region.

Report includes

  • Detailed review of the global auto-injector market within the medical device industry

  • Analyzes of global market trends, with data from 2019-2020, estimates for 2021, and forecasts for compound annual growth rates to 2026

  • Assessment and forecasting of the total size of the Automated Injectors market in dollar terms, analyzing the corresponding market share by product type, management route, treatment, end user, and region

  • Discuss key market dynamics (DROs), technology advancements, regulatory scenario, price analysis, and the competitive environment of the vendor companies.

  • Country-specific data and market value analysis for the US, Canada, UK, France, Germany, Italy, Spain, Japan, China and India

  • Insights into recent industry strategies, key M&A deals, the competitive landscape of the company, and value share analysis of the major players operating in the global Automated Pumps market

  • It highlights the market potential of Automated Injectors, opportunities and gaps estimating current and future demand, and the impact of COVID-19 on the progress of this market

  • Discussing the intensity of competition among the major market participants, their global rankings and recent developments in the Automated Injector market

  • Company profile descriptions for major auto-injector manufacturers and suppliers including AbbVie Inc. and Amgen Inc. and Becton, Dickinson and Co. and Eli Lilly, GlaxoSmithKline PLC, Johnson & Johnson, Merck KGaA, and Teva Pharmaceutical

Main topics covered:

Chapter 1 Introduction

Chapter 2 summary and highlights

Chapter 3 Market and Technology Background

  • an introduction

  • market development

Chapter 4 Impact of the COVID-19 Pandemic

Chapter 5 Market Dynamics

  • summary

  • High incidence of anaphylaxis

  • Targeted therapies are on the rise

  • market restrictions

  • There are alternative routes for drug delivery

  • Strict regulatory scenario

Chapter 6 Market Breakdown by Product Type

Chapter 7 Market breakdown by management path

Chapter 8 Market Breakdown by Cure

  • Squeamishness

  • Market size and forecast

  • Rheumatoid arthritis

  • multiple sclerosis

  • diabetic

Chapter 9 Market breakdown by end user

  • home care settings

  • Market size and forecast

  • Hospitals and clinics

  • ambulatory care settings

Chapter 10 Market Distribution by Region

  • North Amarica

  • United States of America

  • Canada

  • Europe

  • Germany

  • United kingdom

  • France

  • Italy

  • Spain

  • Rest of Europe

  • Asia Pacific

  • China

  • Japan

  • India

  • Rest of Asia and the Pacific

  • Latin america

  • Middle East and Africa

Chapter 11 Regulatory Scenarios

  • Definition and classification of medical devices

  • Regulations in the United States

  • Code of Federal Regulations

  • Federal regulations electronic code

  • Pre-Market Notice 510(k) Market Clearance

  • 510(k) Exempt Appliances

  • Market pre-approval

  • European regulations

  • Organizing in North America

  • US regulations

  • Canadian regulations

  • organization in latin america

  • Organization in Asia and the Pacific

  • future regulatory directions

Chapter 12 The Competitive Scene

Chapter 13 Company Profiles

  • Abbvie Inc.

  • Amgen Inc.

  • Antares Pharma Inc

  • Becton, Dickinson & Company.

  • Eli Lilly And Co.

  • GlaxoSmithKline Inc

  • Johnson & Johnson

  • Merck Kja

  • SHL Medical Ag

  • Teva Pharmaceutical Industries Ltd.

  • Lipsomed

For more information about this report visit

View the source version on

Laura Wood, Senior Director of Press
For EST office hours, call 1-917-300-0470
For US/Canada Toll Free Call 1-800-526-8630
For GMT office hours, call +353-1-416-8900

Write a Comment